麦考酚酸酯在肾移植中的应用

Application of mycophenolate mofetil in renal transplantation

目的：观察麦考酚酸酯（ ｍｙｍcoｐｈｅｎｏｌａｔｅｍｏｆｅｔｉｌ，ＭＭＦ）预防移植肾急性排斥的安全性及有效性。方法：４０例肾移植病人分为２组，２０例［男性１２例，女性 ８例，年龄（４３ ± ｓ １０） ａ］为治疗组，给予ＭＭＦ1ｇ， ｐｏ， ｂｉｄ；另 ２０例［男性 １３例，女性 ７例，年龄（４５±１１） ａ］为对照组，给予硫唑嘌呤（Ａｚａ） １５０ｍｐ，ｐｏ， ｑｎ。共 ６ ｍｏ。结果： ＭＭＦ组急性排斥反应发生率为０，Ａｚａ组为２例，２组间差异无显著意义（Ｐ＞０．０５）。２组病人的消化道反应、肝中毒、感染等并发症的发生率的差异无显著意义（Ｐ＞０．０５）。结论：ＭＭＦ是一种能预防移植肾急性排斥反应的安全、有效的免疫抑制剂。

To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in the prevention of acute rejection in renal transplantation. METHODS: Forty patients after renal transplantation were divided into 2 groups. Twenty Patients (M 12, F 8, age: 43 a± s 10 a) in treatment group received MMF ig, po, bid, and the other 20 patients (M 13, F 7, age 45 a ± 11 a) received azathioprine (Aza) 150 mg, po, qn, as control. The study lasted for 6 mo. RESULTS: The incidence of acute rejection of MMF group was 0, and of Aza group was 10%, no significant difference was found between the 2 groups (P > 0. 05 ). Side effects in digestive system, liver, and including infections were similar in 2 groups (P > 0. 05 ). CONCLUSION: MMF is an effective and safe immunosuppressant for prevention of acute rejection in renal transplantation.